<code id='D6476D7DFD'></code><style id='D6476D7DFD'></style>
    • <acronym id='D6476D7DFD'></acronym>
      <center id='D6476D7DFD'><center id='D6476D7DFD'><tfoot id='D6476D7DFD'></tfoot></center><abbr id='D6476D7DFD'><dir id='D6476D7DFD'><tfoot id='D6476D7DFD'></tfoot><noframes id='D6476D7DFD'>

    • <optgroup id='D6476D7DFD'><strike id='D6476D7DFD'><sup id='D6476D7DFD'></sup></strike><code id='D6476D7DFD'></code></optgroup>
        1. <b id='D6476D7DFD'><label id='D6476D7DFD'><select id='D6476D7DFD'><dt id='D6476D7DFD'><span id='D6476D7DFD'></span></dt></select></label></b><u id='D6476D7DFD'></u>
          <i id='D6476D7DFD'><strike id='D6476D7DFD'><tt id='D6476D7DFD'><pre id='D6476D7DFD'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:2985
          NASDAQ
          Spencer Platt/Getty Images

          Emergent BioSolutions, the manufacturing company that fell into hot water in 2021 due to a contamination issue involving millions of doses of Covid vaccines, is pivoting its business and cutting hundreds of jobs, including a C-suite role.

          The company announced Tuesday that it will cut 400 jobs and eliminate the role of chief operating officer as part of a shift away from its contract manufacturing services business. The current chief operating officer, Adam Havey, will leave the company on Sept. 30.

          advertisement

          Instead, Emergent will focus on producing Narcan nasal spray and other products. The overdose reversal medicine became available as an over-the-counter medicine earlier this year.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more
          The boys, now 6, who are gene therapy’s ‘edge case’ problem
          The boys, now 6, who are gene therapy’s ‘edge case’ problem

          HiramSecrist(left),whohasDuchennemusculardystrophy,withhismother,KristenSecrist(center),andhisgrandm

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Moderna hits safety problems in bold bid to reinvent medicine

          AramBoghosianforSTATSANFRANCISCO—ModernaTherapeutics,themosthighlyvaluedprivatecompanyinbiotech,hasr